Egene Inc (fka EGEI)

[ProfitScout]

The Bellwether Report Begins Due-Diligence on eGene Inc

May 05, 2006 (M2 PRESSWIRE via COMTEX) -- eGene Inc (OTCBB: EGEI), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.

eGene Inc focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing, yesterday afternoon they announce its HDA-GT12 Genetic Analyzer shows compatibility of detecting the influenza A virus, commonly known as the avian flu virus.

The automatic analysis process is less than six minutes. The company has demonstrated that its system platform can handle 12 RT-PCR amplified virus samples in six minutes, or at a sample analysis rate of two samples per minute.

The virus naturally infects humans and other mammalian species such as swine, horse and avian species," said Dr. Ming Liu, acting CEO of the company. "The concerns of a human outbreak of the avian influenza virus have raised significant concerns. Our system can rapidly detect whether we are dealing with an ordinary flu strain or the more serious avian strain. Furthermore, genetic analysis is one of the effective ways to determine whether the virus has mutated to a point where it is dangerous to humans. The need to perform this analysis rapidly cannot be understated in today's world where an airplane ride can transmit a virus thousands of miles in a short period of time."

"The virus naturally infects humans and other mammalian species such as swine, horse and avian species," said Dr. Ming Liu, acting CEO of the company. "The concerns of a human outbreak of the avian influenza virus have raised significant concerns. Our system can rapidly detect whether we are dealing with an ordinary flu strain or the more serious avian strain.

Furthermore, genetic analysis is one of the effective ways to determine whether the virus has mutated to a point where it is dangerous to humans. The need to perform this analysis rapidly cannot be understated in today's world where an airplane ride can transmit a virus thousands of miles in a short period of time."

The HDA-GT12 system uses a consumable multi-channel cartridge that can be used to detect multiple influenza samples simultaneously. The cartridge is engaged to eGene's system and can automatically inject and analyze 12 DNA samples at the same time for results available in six minutes, or for 96 samples from a PCR plate for results available in 50 minutes -- less than an hour.

"This automated and affordable system can be easily operated for avian influenza virus detection," said Dr. Liu.

He noted that eGene recently tested its system utilizing the reagents from In-Vitro Diagnostic FluAVision kits provided by DNA Technology A/S (Denmark). Positive control of influenza A from the testing kit was used for amplification and analyzed with the eGene HDA-GT12 system.

Previously, eGene explained that its analyzer, if placed in airports and other ports of entry throughout the world, can be used to determine if the flu virus is present in the DNA samples of travelers entering -- or leaving -- a given locale.

"The fact that our compact, low-cost, automated digital genetic analysis system platform can do the detection and analysis work in a short time means that should a flu pandemic break out, our system could easily detect and notify officials of a virus carrier who may not be exhibiting physical symptoms of the flu. This is very important, because with illnesses like the flu, the virus is already present and multiplying even in the absence of physical symptoms," explained Dr. Liu. "This could potentially stop the spread of the flu."

Following this announcement, eGene Inc, instantly took off as it trade from $.just below $0.80 to above$1.40 in the last half hour of trading on huge volume. Since then the company has corrected itself a bit as it currently trades at $0.99 on volume of 393,933 shares. I feel that this company could be a great trading opportunity ,especially on this bounce as the Bird Flu continues to spread with birds beginning to migrate for the summer months. The BWR Research Team will continue to follow the market sentiment on this company and numerous others.

To review research on large cap companies like eGene Inc, as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!

The Bellwether Report will continue to research all of the markets to bring you exciting opportunities!! If you are interested in receiving more information on these small or large cap opportunities as well as other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.

Companies looking to advertise with Bellwether Report should email [e-mail] with the subject line (Advertising).

All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to [e-mail].


(C)1994-2006 M2 COMMUNICATIONS LTD